血流储备分数与瞬时无波形比值对稳定冠心病PCI安慰剂对照疗效的预测价值
ORBITA-2试验纳入279例稳定冠心病心绞痛患者,停用抗心绞痛药物后随机接受PCI或安慰剂,随访12周每日记录心绞痛。FFR和iFR越低,PCI较安慰剂的症状改善越显著,提示生理学狭窄严重程度可预测PCI获益。
要点
- FFR和iFR越低,PCI较安慰剂的心绞痛症状改善越显著。
- FFR下四分位(0.46)对心绞痛症状评分的安慰剂对照改善优于上四分位(0.73),OR 2.01。
- 生理学指标可用于筛选最可能从PCI获益的患者。
核心结论
- FFR和iFR测定的生理学狭窄严重程度可预测PCI的安慰剂对照心绞痛缓解。
- 有创冠状动脉生理学可用于筛选最可能从PCI获益的患者。
研究设计与样本
- ORBITA-2为安慰剂对照随机试验,纳入有心绞痛、缺血和稳定冠心病的患者,停用抗心绞痛药物。
- 279例患者有创生理学数据可用(PCI组140例,安慰剂组139例),随机后进入12周盲法随访,每日通过ORBITA智能手机应用报告心绞痛。
- 采用贝叶斯比例优势模型检验FFR和iFR作为连续变量预测PCI安慰剂对照效应的能力。
主要发现
- 中位年龄65岁(IQR 59.0-70.5),男性223例(79.9%)。
- 中位FFR为0.60(IQR 0.46-0.73),中位iFR为0.76(IQR 0.50-0.86)。
- FFR或iFR越低,PCI在所有终点上的安慰剂对照改善越大。
- FFR下四分位(0.46)对比上四分位(0.73),心绞痛症状评分的安慰剂对照改善OR为2.01(95%可信区间1.79-2.26),交互作用概率>99.9%。
- iFR下四分位(0.50)对比上四分位(0.86),心绞痛症状评分的安慰剂对照改善OR为2.13(95%可信区间1.87-2.45),交互作用概率>99.9%。
关键数值与推荐
- FFR下四分位0.46对比上四分位0.73,心绞痛症状评分安慰剂对照改善OR 2.01(95%可信区间1.79-2.26)。
- iFR下四分位0.50对比上四分位0.86,心绞痛症状评分安慰剂对照改善OR 2.13(95%可信区间1.87-2.45)。
- FFR和iFR与获益的关系在Rose心绞痛和Rose非心绞痛中均可见。
临床怎么用
- 可使用FFR和iFR评估稳定冠心病患者生理学狭窄严重程度,以筛选最可能从PCI获得心绞痛缓解的患者。
- FFR或iFR较低的患者,PCI的安慰剂对照心绞痛改善更显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ORBITA-2 (the Placebo-Controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable coronary artery disease. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are often used to guide PCI; however, their ability to predict placebo-controlled angina improvement is unknown. METHODS: Participants with angina, ischemia, and stable coronary artery disease were enrolled, and anti-anginal medications were stopped. Participants reported angina episodes daily for 2 weeks using the ORBITA smartphone symptom application (ORBITA-app). At the research angiogram, FFR and iFR were measured. After sedation and auditory isolation, participants were randomized to PCI or placebo before entering a 12-week blinded follow-up phase with daily angina reporting. The ability of FFR and iFR, analyzed as continuous variables, to predict the placebo-controlled effect of PCI was tested using Bayesian proportional odds modeling. RESULTS: Invasive physiology data were available for 279 patients (140 PCI and 139 placebo). The median (interquartile range) age was 65 years (59.0-70.5), and 223 (79.9%) were male. Median FFR was 0.60 (0.46-0.73), and median iFR was 0.76 (0.50-0.86). The lower the FFR or iFR, the greater the placebo-controlled improvement with PCI across all end points. There was strong evidence that a patient with an FFR at the lower quartile would have a greater placebo-controlled improvement in angina symptom score with PCI than a patient at the upper quartile (FFR, 0.46 versus 0.73: odds ratio, 2.01; 95% credible interval, 1.79-2.26; probability of interaction, >99.9%). Similarly, there was strong evidence that a patient with an iFR at the lower quartile would have greater placebo-controlled improvement in angina symptom score with PCI than a patient with an iFR at the upper quartile (iFR, 0.50 versus 0.86: odds ratio, 2.13; 95% credible interval, 1.87-2.45; probability of interaction, >99.9%). The relationship between benefit and physiology was seen in both Rose angina and Rose nonangina. CONCLUSIONS: Physiological stenosis severity, as measured by FFR and iFR, predicts placebo-controlled angina relief from PCI. Invasive coronary physiology can be used to target PCI to those patients who are most likely to experience benefit. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03742050.
引用
- Foley MJ, Rajkumar CA, Ahmed-Jushuf F, et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Circulation. 2024. PMID: 39462291. doi:10.1161/CIRCULATIONAHA.124.072281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。